Trials / Terminated
TerminatedNCT05061940
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Screening Protocol to Assess the Expression of Tumor Associated Antigens (TAAs), Human Papillomavirus (HPV-16) Antigens and Human Leucocyte Antigen (HLA) Sub-Types in Patients With Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers.
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 22 (actual)
- Sponsor
- Repertoire Immune Medicines · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.
Detailed description
This screening study is intended for men and women at least 18 years of age who have selected advanced solid tumors. The study will assess the patient's selected tumor antigens and/or HPV-16 E6/E7 expression profiles. Human leukocyte antigen (HLA) subtype will also be assessed. Based on the results, it will be determined if a patient is eligible to be considered for a Repertoire Immune Medicines sponsored clinical trial(s) testing of the safety and efficacy of a multi-antigen cytokine-enhanced T cell therapy. No treatment intervention will occur as part of this screening study. Upon enrollment, patients will be required to provide archival tumor tissue and saliva samples. Based upon the results of these diagnostic analyses, if eligible, patients may be enrolled in an appropriate interventional clinical trial(s) at the discretion of the Investigator.
Conditions
- Head and Neck Cancer
- Melanoma
- HPV-Related Malignancy
- HPV-Related Carcinoma
- HPV-Related Cervical Carcinoma
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Lung Cancer, Nonsmall Cell
- Melanoma (Skin)
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Tumor Profiling | Testing TAA and HPV expression. HLA typing. |
Timeline
- Start date
- 2021-05-05
- Primary completion
- 2022-10-11
- Completion
- 2022-10-11
- First posted
- 2021-09-30
- Last updated
- 2022-12-06
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05061940. Inclusion in this directory is not an endorsement.